Azurity Drug Patent Portfolio

Azurity owns 23 orange book drugs protected by 101 US patents with Myhibbin having the least patent protection, holding only 1 patent. And Katerzia with maximum patent protection, holding 11 patents. Given below is the list of Azurity's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11844784 Stable pharmaceutical compositions of bendamustine 29 Jul, 2042
Active
US11433046 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
Active
US11633374 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
Active
US11826343 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
Active
US11911362 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
Active
US11771686 Compositions and kits for omeprazole suspension 01 Mar, 2040
Active
US11931455 Pharmaceutical suspension for oral dosage 16 Aug, 2039
Active
US10751333 Compositions and kits for omeprazole suspension 16 Jul, 2039
Active
US11103492 Compositions and kits for omeprazole suspension 16 Jul, 2039
Active
US11633478 Compositions and kits for Omeprazole suspension 16 Jul, 2039
Active
US11911473 Compositions and kits for omeprazole suspension 16 Jul, 2039
Active
US12042539 Compositions and kits for Omeprazole suspension 16 Jul, 2039
Active
US10799453 Amlodipine formulations 11 Apr, 2039
Active
US11311554 Pharmaceutical compositions of testosterone 25 Mar, 2039
Active
US11642355 Pharmaceutical compositions of testosterone 25 Mar, 2039
Active
US10456354 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
Active
US11110054 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
Active
US11938217 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
Active
US11478456 Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof 18 Aug, 2038
Active
US11529333 Oral pharmaceutical composition comprising zonisamide and process of preparation thereof 18 Aug, 2038
Active
US10342787 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US10576070 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US11207306 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US11413277 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US11517563 Liquid nimodipine compositions 16 Apr, 2038
Active
US11759457 Liquid nimodipine compositions 16 Apr, 2038
Active
US11806338 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US10695329 Amlodipine formulations 16 Oct, 2037
Active
US10894039 Amlodipine formulations 06 Oct, 2037
Active
US10952998 Amlodipine formulations 06 Oct, 2037
Active
US10959991 Amlodipine formulations 06 Oct, 2037
Active
US11364230 Amlodipine formulations 06 Oct, 2037
Active
US11471409 Amlodipine formulations 06 Oct, 2037
Active
US11484498 Amlodipine formulations 06 Oct, 2037
Active
US11701326 Amlodipine formulations 06 Oct, 2037
Active
US11918685 Amlodipine formulations 06 Oct, 2037
Active
US12053461 Amlodipine formulations 06 Oct, 2037
Active
US11324696 Suspensions and diluents for metronidazole and baclofen 29 Sep, 2037
Active
US11446246 Suspensions and diluents for metronidazole and baclofen 08 Sep, 2037
Active
US10441554 Oral amphetamine composition 10 Mar, 2037
Active
US11160772 Oral amphetamine composition 10 Mar, 2037
Active
US11896562 Oral amphetamine composition 10 Mar, 2037
Active
US10039745 Enalapril formulations 25 Mar, 2036
Active
US10154987 Enalapril formulations 25 Mar, 2036
Active
US10772868 Enalapril formulations 25 Mar, 2036
Active
US10786482 Enalapril formulations 25 Mar, 2036
Active
US11040023 Enalapril formulations 25 Mar, 2036
Active
US11141405 Enalapril formulations 25 Mar, 2036
Active
US11173141 Enalapril formulations 25 Mar, 2036
Active
US9669008 Enalapril formulations 25 Mar, 2036
Active
US9808442 Enalapril formulations 25 Mar, 2036
Active
US10039800 Lisinopril formulations 06 Nov, 2035
Active
US10265370 Lisinopril formulations 06 Nov, 2035
Active
US10406199 Lisinopril formulations 06 Nov, 2035
Active
US10940177 Lisinopril formulations 06 Nov, 2035
Active
US11179434 Lisinopril formulations 06 Nov, 2035
Active
US11771733 Lisinopril formulations 06 Nov, 2035
Active
US9463183 Lisinopril formulations 06 Nov, 2035
Active
US9616096 Lisinopril formulations 06 Nov, 2035
Active
US9814751 Lisinopril formulations 06 Nov, 2035
Active
US9724297 Sotalol compositions and uses of the same 31 Aug, 2035
Active
US10493028 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US10688046 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US10959946 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US10959947 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US10959948 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US10959949 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US11638692 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US11850222 Sotalol compositions and uses of the same 19 Nov, 2034
Active
US10206895 Sotalol compositions and uses of the same 01 Apr, 2034
Active
US11013703 Sotalol compositions and uses of the same 01 Apr, 2034
Active
US10231927 Methotrexate composition 02 Jan, 2033
Active
US10610485 Methotrexate composition 02 Jan, 2033
Active
US11116724 Methotrexate composition 02 Jan, 2033
Active
US11969503 Methotrexate composition 02 Jan, 2033
Active
US9259427 Methotrexate composition 02 Jan, 2033
Active
US9855215 Methotrexate composition 02 Jan, 2033
Active
US8568747 Enalapril compositions 06 Nov, 2032
Active
US8778366 Enalapril compositions 06 Nov, 2032
Active
US9855214 Enalapril compositions 06 Nov, 2032
Active
US9968553 Enalapril compositions 06 Nov, 2032
Active
US9050307 Method for the preparation of a levothyroxine solution 06 Aug, 2031
Active
US9387249 Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone 01 Jul, 2031
Active
US9169238 Solid pharmaceutical composition 04 Feb, 2030
Active
US10166181 Slow release pharmaceutical composition made of microgranules 30 Jun, 2029
Active
US8795725 GABA analog prodrug sustained release oral dosage forms 10 Jun, 2029
Active
US9066936 Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent 26 Mar, 2028
Active
US8026279 Crystalline form of γ-aminobutyric acid analog 10 Nov, 2026
Active
US8114909 Treating or preventing restless legs syndrome using prodrugs of GABA analogs 11 Apr, 2026
Active
US7157584 Benzimidazole derivative and use thereof 22 May, 2025
Active
US6818787 Prodrugs of GABA analogs, compositions and uses thereof 06 Apr, 2025
Active
US8686034 Crystalline form of γ-aminobutyric acid analog 24 Jan, 2025
Active
US7572920 Benzimidazole derivative and use as a II receptor antagonist 07 Jan, 2025
Active
US8517997 Dispenser for medicaments and method and apparatus for making same 14 May, 2024 Expired
US10130580 Taste-masked pharmaceutical compositions 19 Apr, 2024 Expired
US7070581 Dispenser for medicaments and method and apparatus for making same 23 Jun, 2023 Expired
US8048917 Prodrugs of GABA analogs, compositions and uses thereof 06 Nov, 2022 Expired
US6465463 Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate 08 Sep, 2020 Expired
US6784177 Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate 08 Sep, 2020 Expired
US5958961 Pharmaceutical composition for angiotensin II-mediated diseases 06 Jun, 2014 Expired
US5583141 Heterocyclic compounds and their use as angiotensin antagonists 10 Dec, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Azurity.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 15 Apr, 2024 US10799453
Payment of Maintenance Fee, 8th Year, Large Entity 11 Apr, 2024 US9463183
Payment of Maintenance Fee, 4th Year, Large Entity 29 Mar, 2024 US10786482
Patent Issue Date Used in PTA Calculation 26 Mar, 2024 US11938217
Mail Patent eGrant Notification 26 Mar, 2024 US11938217
Patent eGrant Notification 26 Mar, 2024 US11938217
Recordation of Patent Grant Mailed 26 Mar, 2024 US11938217
Email Notification 26 Mar, 2024 US11938217
Recordation of Patent eGrant 26 Mar, 2024 US11938217
Email Notification 07 Mar, 2024 US11938217
Issue Notification Mailed 06 Mar, 2024 US11938217
Patent Issue Date Used in PTA Calculation 05 Mar, 2024 US11918685
Recordation of Patent Grant Mailed 05 Mar, 2024 US11918685
Recordation of Patent eGrant 05 Mar, 2024 US11918685
Mail Patent eGrant Notification 05 Mar, 2024 US11918685


Azurity's Drug Patent Litigations

Azurity's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 10, 2017, against patent number US9463183. The petitioner KVK-Tech, Inc., challenged the validity of this patent, with Silvergate Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Azurity's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9463183 July, 2017 FWD Entered
(07 May, 2018)
Silvergate Pharmaceuticals, Inc. KVK-Tech, Inc.


Azurity Drug Patents' Oppositions Filed in EPO

Azurity drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 04, 2008, by Breuer, Markus. This opposition was filed on patent number EP02744314A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP12172232A Apr, 2019 Generics [UK] Ltd Granted and Under Opposition
EP08763237A Sep, 2017 Ferring B.V. Revoked
EP08763237A Sep, 2017 Generics (UK) Ltd Revoked
EP11711688A Jul, 2016 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Granted and Under Opposition
EP02744314A Sep, 2008 Breuer, Markus Patent maintained as amended


Azurity's Family Patents

Azurity drugs have patent protection in a total of 50 countries. It's US patent count contributes only to 38.0% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Azurity Drug List

Given below is the complete list of Azurity's drugs and the patents protecting them.


1. Bidil

Bidil is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6465463 Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate 08 Sep, 2020
(4 years ago)
Expired
US6784177 Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate 08 Sep, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bidil's drug page


2. Edarbi

Edarbi is protected by 5 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9066936 Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent 26 Mar, 2028
(3 years from now)
Active
US7157584 Benzimidazole derivative and use thereof 22 May, 2025
(7 months from now)
Active
US7572920 Benzimidazole derivative and use as a II receptor antagonist 07 Jan, 2025
(3 months from now)
Active
US5958961 Pharmaceutical composition for angiotensin II-mediated diseases 06 Jun, 2014
(10 years ago)
Expired
US5583141 Heterocyclic compounds and their use as angiotensin antagonists 10 Dec, 2013
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edarbi's drug page


3. Edarbyclor

Edarbyclor is protected by 6 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9387249 Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone 01 Jul, 2031
(6 years from now)
Active
US9169238 Solid pharmaceutical composition 04 Feb, 2030
(5 years from now)
Active
US9066936 Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent 26 Mar, 2028
(3 years from now)
Active
US7157584 Benzimidazole derivative and use thereof 22 May, 2025
(7 months from now)
Active
US7572920 Benzimidazole derivative and use as a II receptor antagonist 07 Jan, 2025
(3 months from now)
Active
US5583141 Heterocyclic compounds and their use as angiotensin antagonists 10 Dec, 2013
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edarbyclor's drug page


4. Epaned

Epaned is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039745 Enalapril formulations 25 Mar, 2036
(11 years from now)
Active
US10154987 Enalapril formulations 25 Mar, 2036
(11 years from now)
Active
US10772868 Enalapril formulations 25 Mar, 2036
(11 years from now)
Active
US10786482 Enalapril formulations 25 Mar, 2036
(11 years from now)
Active
US11040023 Enalapril formulations 25 Mar, 2036
(11 years from now)
Active
US11141405 Enalapril formulations 25 Mar, 2036
(11 years from now)
Active
US11173141 Enalapril formulations 25 Mar, 2036
(11 years from now)
Active
US9669008 Enalapril formulations 25 Mar, 2036
(11 years from now)
Active
US9808442 Enalapril formulations 25 Mar, 2036
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epaned's drug page


5. Epaned Kit

Epaned Kit is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8568747 Enalapril compositions 06 Nov, 2032
(8 years from now)
Active
US8778366 Enalapril compositions 06 Nov, 2032
(8 years from now)
Active
US9855214 Enalapril compositions 06 Nov, 2032
(8 years from now)
Active
US9968553 Enalapril compositions 06 Nov, 2032
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epaned Kit's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Eprontia

Eprontia is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11433046 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
(15 years from now)
Active
US11633374 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
(15 years from now)
Active
US11826343 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
(15 years from now)
Active
US11911362 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
(15 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eprontia's drug page


7. Evekeo Odt

Evekeo Odt is protected by 4 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10441554 Oral amphetamine composition 10 Mar, 2037
(12 years from now)
Active
US11160772 Oral amphetamine composition 10 Mar, 2037
(12 years from now)
Active
US11896562 Oral amphetamine composition 10 Mar, 2037
(12 years from now)
Active
US10130580 Taste-masked pharmaceutical compositions 19 Apr, 2024
(5 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evekeo Odt's drug page


8. Firvanq Kit

Firvanq Kit is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10493028 Composition and method for vancomycin oral liquid 13 Mar, 2035
(10 years from now)
Active
US10688046 Composition and method for vancomycin oral liquid 13 Mar, 2035
(10 years from now)
Active
US10959946 Composition and method for vancomycin oral liquid 13 Mar, 2035
(10 years from now)
Active
US10959947 Composition and method for vancomycin oral liquid 13 Mar, 2035
(10 years from now)
Active
US10959948 Composition and method for vancomycin oral liquid 13 Mar, 2035
(10 years from now)
Active
US10959949 Composition and method for vancomycin oral liquid 13 Mar, 2035
(10 years from now)
Active
US11638692 Composition and method for vancomycin oral liquid 13 Mar, 2035
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Firvanq Kit's drug page


9. Fleqsuvy

Fleqsuvy is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11324696 Suspensions and diluents for metronidazole and baclofen 29 Sep, 2037
(12 years from now)
Active
US11446246 Suspensions and diluents for metronidazole and baclofen 08 Sep, 2037
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fleqsuvy's drug page


10. Horizant

Horizant is protected by 6 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8795725 GABA analog prodrug sustained release oral dosage forms 10 Jun, 2029
(4 years from now)
Active
US8026279 Crystalline form of γ-aminobutyric acid analog 10 Nov, 2026
(2 years from now)
Active
US8114909 Treating or preventing restless legs syndrome using prodrugs of GABA analogs 11 Apr, 2026
(1 year, 6 months from now)
Active
US6818787 Prodrugs of GABA analogs, compositions and uses thereof 06 Apr, 2025
(5 months from now)
Active
US8686034 Crystalline form of γ-aminobutyric acid analog 24 Jan, 2025
(3 months from now)
Active
US8048917 Prodrugs of GABA analogs, compositions and uses thereof 06 Nov, 2022
(1 year, 10 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Horizant's drug page


11. Katerzia

Katerzia is protected by 11 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10799453 Amlodipine formulations 11 Apr, 2039
(14 years from now)
Active
US10695329 Amlodipine formulations 16 Oct, 2037
(13 years from now)
Active
US10894039 Amlodipine formulations 06 Oct, 2037
(13 years from now)
Active
US10952998 Amlodipine formulations 06 Oct, 2037
(13 years from now)
Active
US10959991 Amlodipine formulations 06 Oct, 2037
(13 years from now)
Active
US11364230 Amlodipine formulations 06 Oct, 2037
(13 years from now)
Active
US11471409 Amlodipine formulations 06 Oct, 2037
(13 years from now)
Active
US11484498 Amlodipine formulations 06 Oct, 2037
(13 years from now)
Active
US11701326 Amlodipine formulations 06 Oct, 2037
(13 years from now)
Active
US11918685 Amlodipine formulations 06 Oct, 2037
(13 years from now)
Active
US12053461 Amlodipine formulations 06 Oct, 2037
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Katerzia's drug page


12. Konvomep

Konvomep is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11771686 Compositions and kits for omeprazole suspension 01 Mar, 2040
(15 years from now)
Active
US10751333 Compositions and kits for omeprazole suspension 16 Jul, 2039
(14 years from now)
Active
US11103492 Compositions and kits for omeprazole suspension 16 Jul, 2039
(14 years from now)
Active
US11633478 Compositions and kits for Omeprazole suspension 16 Jul, 2039
(14 years from now)
Active
US11911473 Compositions and kits for omeprazole suspension 16 Jul, 2039
(14 years from now)
Active
US12042539 Compositions and kits for Omeprazole suspension 16 Jul, 2039
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Konvomep's drug page


13. Myhibbin

Myhibbin is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11931455 Pharmaceutical suspension for oral dosage 16 Aug, 2039
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myhibbin's drug page


14. Nymalize

Nymalize is protected by 9 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10342787 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(13 years from now)
Active
US10576070 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(13 years from now)
Active
US11207306 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(13 years from now)
Active
US11413277 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(13 years from now)
Active
US11517563 Liquid nimodipine compositions 16 Apr, 2038
(13 years from now)
Active
US11759457 Liquid nimodipine compositions 16 Apr, 2038
(13 years from now)
Active
US11806338 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(13 years from now)
Active
US8517997 Dispenser for medicaments and method and apparatus for making same 14 May, 2024
(4 months ago)
Expired
US7070581 Dispenser for medicaments and method and apparatus for making same 23 Jun, 2023
(1 year, 3 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nymalize's drug page


15. Prevduo

Prevduo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10456354 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
(14 years from now)
Active
US11110054 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
(14 years from now)
Active
US11938217 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prevduo's drug page


16. Qbrelis

Qbrelis is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039800 Lisinopril formulations 06 Nov, 2035
(11 years from now)
Active
US10265370 Lisinopril formulations 06 Nov, 2035
(11 years from now)
Active
US10406199 Lisinopril formulations 06 Nov, 2035
(11 years from now)
Active
US10940177 Lisinopril formulations 06 Nov, 2035
(11 years from now)
Active
US11179434 Lisinopril formulations 06 Nov, 2035
(11 years from now)
Active
US11771733 Lisinopril formulations 06 Nov, 2035
(11 years from now)
Active
US9463183 Lisinopril formulations 06 Nov, 2035
(11 years from now)
Active
US9616096 Lisinopril formulations 06 Nov, 2035
(11 years from now)
Active
US9814751 Lisinopril formulations 06 Nov, 2035
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qbrelis's drug page


17. Sotylize

Sotylize is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9724297 Sotalol compositions and uses of the same 31 Aug, 2035
(10 years from now)
Active
US11850222 Sotalol compositions and uses of the same 19 Nov, 2034
(10 years from now)
Active
US10206895 Sotalol compositions and uses of the same 01 Apr, 2034
(9 years from now)
Active
US11013703 Sotalol compositions and uses of the same 01 Apr, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sotylize's drug page


18. Testosterone Cypionate

Testosterone Cypionate is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11311554 Pharmaceutical compositions of testosterone 25 Mar, 2039
(14 years from now)
Active
US11642355 Pharmaceutical compositions of testosterone 25 Mar, 2039
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Testosterone Cypionate's drug page


19. Thyquidity

Thyquidity is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9050307 Method for the preparation of a levothyroxine solution 06 Aug, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Thyquidity's drug page


20. Triptodur Kit

Triptodur Kit is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10166181 Slow release pharmaceutical composition made of microgranules 30 Jun, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Triptodur Kit's drug page


21. Vivimusta

Vivimusta is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11844784 Stable pharmaceutical compositions of bendamustine 29 Jul, 2042
(17 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vivimusta's drug page


22. Xatmep

Xatmep is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10231927 Methotrexate composition 02 Jan, 2033
(8 years from now)
Active
US10610485 Methotrexate composition 02 Jan, 2033
(8 years from now)
Active
US11116724 Methotrexate composition 02 Jan, 2033
(8 years from now)
Active
US11969503 Methotrexate composition 02 Jan, 2033
(8 years from now)
Active
US9259427 Methotrexate composition 02 Jan, 2033
(8 years from now)
Active
US9855215 Methotrexate composition 02 Jan, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xatmep's drug page


23. Zonisade

Zonisade is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11478456 Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof 18 Aug, 2038
(13 years from now)
Active
US11529333 Oral pharmaceutical composition comprising zonisamide and process of preparation thereof 18 Aug, 2038
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zonisade's drug page